A study assessed the association of cardiovascular disease (CVD) risk scores and coronary artery plaque (CAP) progression in HIV-infected participants. The results appeared in the journal AIDS.
Researchers analyzed a total of 495 men with (n=211) and without (n=284) HIV-infection who were enrolled in the Multicenter AIDS Cohort Study (MACS) CVD study. They assessed coronary artery plaque (CAP) at baseline and follow-up was assessed with cardiac computed tomography angiography (CCTA). The association between baseline risk scores including pooled cohort equation (PCE), Framingham risk score (FRS) and Data collect of Adverse effects of anti-HIV drugs equation (D:A:D) and CAP progression.
The researchers showed that among HIV-infected men, the association for total plaque volume (TPV) TPV and non-calcified plaque volume (NCPV) progression for the same PCE risk categories, OR 2.8 (1.4, 5.8, p < 0.01) and OR 2.4 (1.2, 4.8, p < 0.05) respectively (p-values for interaction by HIV = 0.02 and 0.08, respectively). The researchers noted that were seen for the FRS risk scores. Among HIV-uninfected men, PCE high risk category identified the highest proportion of men with plaque progression in the highest tertile. While, in HIV-infected men, high risk category by D:A:D identified the greatest percentage of men with plaque progression albeit with lower specificity than FRS and PCE.
“PCE and FRS categories predict CAP progression better in HIV-uninfected compared to HIV-infected men,” the researchers concluded. “Improved CVD risk scores are needed to identify high risk HIV-infected men for more aggressive CVD risk prevention strategies.”